Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

Rasmus M. Christensen, Christian R. Juhl and Signe S. Torekov ()
Additional contact information
Rasmus M. Christensen: University of Copenhagen
Christian R. Juhl: University of Copenhagen
Signe S. Torekov: University of Copenhagen

Drug Safety, 2019, vol. 42, issue 7, No 11, 919-919

Abstract: In the original publication of this article, the following correction should be noted in Table 1.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00830-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:7:d:10.1007_s40264-019-00830-5

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00830-5

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().